Peptide Library

FDA-approved

Skin & aging

Ecallantide

Evidence

FDA approved

Class

Kallikrein inhibitor protein

/

Ecallantide

KEY TAKEAWAY

Ecallantide is a 60-amino-acid recombinant protein that inhibits plasma kallikrein. It is sold as Kalbitor. The FDA approved ecallantide (Kalbitor) in 2009 for acute attacks of hereditary angioedema in people 12 and older.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Kallikrein inhibitor protein

Approved for

Acute attacks of hereditary angioedema

Key fact

The FDA approved ecallantide (Kalbitor) in 2009 for acute attacks of hereditary angioedema in people 12 and older.

Route

Subcutaneous injection given by a healthcare provider

Evidence strength

FDA approved

What it is

What it is

Ecallantide is a 60-amino-acid recombinant protein that inhibits plasma kallikrein. It is sold as Kalbitor.

How it works

How it works

By blocking kallikrein it lowers the production of bradykinin, the molecule that causes swelling during hereditary angioedema attacks.

Regulatory status

Regulatory status

The FDA approved ecallantide (Kalbitor) in 2009 for acute attacks of hereditary angioedema in people 12 and older.

What it is used for

What it is used for

Acute attacks of hereditary angioedema.

Side effects and risks

Side effects and risks

The label carries a boxed warning for serious allergic reactions including anaphylaxis, so a healthcare professional gives it.

Citations

Citations

U.S. FDA prescribing information for Ecallantide. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo